Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer

This is the authors' abstract. We don't add key points for this paper.

In this study, we found that low-prostate-specific antigen, high-grade prostate cancer has a very high risk for prostate cancer death, may not respond well to androgen deprivation therapy, and is associated with neuroendocrine genomic features. These findings suggest that current nomograms and treatment paradigms may need modification.